Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

A long-term shift in U.S. calorie consumption, spurred by rising use of GLP-1 weight-loss drugs, could reduce packaged food and beverage volumes by more than 10%, Bank of America said.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

The singer explained she prefers to call her weight loss journey a process of 'weight release', admitting she tried GLP-1 ...

Ohio to end GLP-1 drug coverage for most state workers without diabetes, citing soaring Medicaid costs and rising demand for ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

Cancer patients are being urged to consult medical professionals before using weight-loss injections, following a significant ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular injectables drugs.